Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Hassel

Showing results (211-220 of 271) with videos related to

Pageof 28
Sort By:
European Journal of Cancer (Oxford, England : 1990)|February 12, 2019
Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastasesRicarda Rauschenberg, Johannes Bruns, Julia Brütting, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2016
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with IpilimumabAlexander Martens, Kilian Wistuba-Hamprecht, Marnix Geukes Foppen, et al.
European Journal of Cancer (Oxford, England : 1990)|February 26, 2026
Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG studyLea Jessica Albrecht, Jana Garnier, Anne Zaremba, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2025
Long-Term Follow-Up of Real-World Adjuvant Anti-PD-1 Checkpoint Inhibition and Targeted Therapy in Patients With Stage III MelanomaGeorg C Lodde, Jessica C Hassel, Imke von Wasielewski, et al.
Journal for Immunotherapy of Cancer|September 22, 2025
ESPEC-SUIT: a versatile and robust platform to identify and track antigen-specific T cell receptors in patients with cancerKatharina Lindner, Saskia R Stange, Julian Benedikt Hlawatsch, et al.
Frontiers of Medicine|July 11, 2023
Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trialElias A T Koch, Anne Petzold, Anja Wessely, et al.
The New England Journal of Medicine|June 6, 2012
Improved survival with MEK inhibition in BRAF-mutated melanomaKeith T Flaherty, Caroline Robert, Peter Hersey, et al.
Frontiers in Immunology|June 25, 2024
Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse eventsElias A T Koch, Anne Petzold, Edgar Dippel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2025
A Phase I, First-in-Human, Dose-Escalation, Expansion Trial of Cytokine-Encoding Synthetic mRNA Mixture Alone or with Cemiplimab in Advanced Solid TumorsOliver Bechter, Carmen Loquai, Stephane Champiat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2016
Baseline Biomarkers for Outcome of Melanoma Patients Treated with PembrolizumabBenjamin Weide, Alexander Martens, Jessica C Hassel, et al.
Pageof 28

Showing results (211-220 of 271) with videos related to

Sort By:
Pageof 28
European Journal of Cancer (Oxford, England : 1990)|February 12, 2019
Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastasesRicarda Rauschenberg, Johannes Bruns, Julia Brütting, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2016
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with IpilimumabAlexander Martens, Kilian Wistuba-Hamprecht, Marnix Geukes Foppen, et al.
European Journal of Cancer (Oxford, England : 1990)|February 26, 2026
Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG studyLea Jessica Albrecht, Jana Garnier, Anne Zaremba, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2025
Long-Term Follow-Up of Real-World Adjuvant Anti-PD-1 Checkpoint Inhibition and Targeted Therapy in Patients With Stage III MelanomaGeorg C Lodde, Jessica C Hassel, Imke von Wasielewski, et al.
Journal for Immunotherapy of Cancer|September 22, 2025
ESPEC-SUIT: a versatile and robust platform to identify and track antigen-specific T cell receptors in patients with cancerKatharina Lindner, Saskia R Stange, Julian Benedikt Hlawatsch, et al.
Frontiers of Medicine|July 11, 2023
Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trialElias A T Koch, Anne Petzold, Anja Wessely, et al.
The New England Journal of Medicine|June 6, 2012
Improved survival with MEK inhibition in BRAF-mutated melanomaKeith T Flaherty, Caroline Robert, Peter Hersey, et al.
Frontiers in Immunology|June 25, 2024
Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse eventsElias A T Koch, Anne Petzold, Edgar Dippel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2025
A Phase I, First-in-Human, Dose-Escalation, Expansion Trial of Cytokine-Encoding Synthetic mRNA Mixture Alone or with Cemiplimab in Advanced Solid TumorsOliver Bechter, Carmen Loquai, Stephane Champiat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2016
Baseline Biomarkers for Outcome of Melanoma Patients Treated with PembrolizumabBenjamin Weide, Alexander Martens, Jessica C Hassel, et al.
Pageof 28